logo
New study makes exciting revelation about health advantages of certain diets: 'Substantial nutritional ... benefits'

New study makes exciting revelation about health advantages of certain diets: 'Substantial nutritional ... benefits'

Yahoo4 hours ago

A new study published in Nature reveals that adopting a plant-rich or vegan diet offers serious benefits for both personal health and the environment.
Researchers in Iceland compared the health and environmental impacts of vegan and omnivorous diets. They found that individuals following a plant-based diet not only met more nutritional recommendations, but also decreased their carbon footprint as a result of avoiding meat-production-related pollution.
However, both groups showed room for improvement in fully meeting dietary recommendations.
While plant-rich diets have long been associated with health benefits, few studies have directly compared vegan diets to omnivorous ones, until now.
The research team analyzed dietary data from 651 omnivores and 68 vegans in Iceland, discovering that the vegan group's diet produced 50% less planet-warming pollution, had nine times higher fiber compliance, and consumed less saturated fat than the meat and dairy consumers.
"Our results also indicate that in our omnivore population a shift towards a more plant-rich diet without eliminating all foods of animal origin could lead to substantial nutritional and environmental benefits," the study concluded.
Another recent study from Harvard Health Publishing involving identical twins found that those on a vegan diet had significantly lower LDL cholesterol and insulin levels, and lost about four pounds — all in just eight weeks.
Even if you're not interested in going vegan, these findings suggest that transitioning to a plant-forward diet can have meaningful effects on both short- and long-term health.
In addition to personal wellness, the environmental impact is substantial. Meat and dairy production are leading contributors to planet-warming emissions, excessive water use, and land degradation globally.
According to the Environmental Protection Agency, agriculture is the top source of methane and nitrous oxide pollution in the U.S., largely stemming from livestock and factory farming. Reducing reliance on animal products, even just a few days a week, can help shrink your environmental impact and support a healthier food system.
Why do you eat plant-based foods?
The health benefits
It's cheaper
It's good for the planet
I prefer the taste
Click your choice to see results and speak your mind.
One Reddit user shared their takeaways from the data: "None of this is surprising, but it's interesting to see studied. I wonder if the gap between vegans and omnivores in [the U.S.] is even bigger due to our factory farm processes."
"Only 5% of omnivores are eating enough fiber?? Yikes," another user added. "No wonder colorectal cancers are on the rise."
Another commenter noted how interesting it was that vegans were closer to meeting macronutrient requirements: "I suspect this is because it's a very conscious dietary choice and is more often actually planned," they said. "Fiber and fats almost take care of themselves."
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors

Yahoo

time2 hours ago

  • Yahoo

Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors

Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

Yahoo

time2 hours ago

  • Yahoo

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Yahoo

time2 hours ago

  • Yahoo

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. lucarista/ The acquisition marks a crucial step in the company's effort to advance the clinical development of a potential first-in-class medicine for autosomal dominant polycystic kidney disease. Regulus Joins Novartis with Farabursen, an investigational next-generation oligonucleotide aiming to reduce the growth of cysts and kidney size. Novartis is a global healthcare company dedicated to discovering and developing innovative medicines that improve and extend people's lives. It also focuses on addressing significant medical challenges, including cancer and rare genetic disorders, by prioritizing research and development, as well as innovative access approaches. Novartis AG (NYSE:NVS) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines to improve and extend people's lives. It also focuses on using science-based innovation to address significant healthcare challenges. Novartis operates in over 100 countries, with the US accounting for about one-third of its revenue. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store